Goldman Sachs
ALT icon

Goldman Sachs’s Altimmune ALT Stock Holding History

Goldman Sachs’s Portfolio ALT Stock Details ALT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-286
Closed -$136K – 6548
2013
Q2 		$136K Buy
+286
New +$142K ﹤0.01% 5769

Other funds holding ALT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Goldman Sachs's ALT Position: Q1 2026 in Review

Goldman Sachs increased its Altimmune (ALT) stake by 0.1% in Q1 2026, buying an estimated $5.76K and bringing the position to 1,350,649 shares worth $4.16M. The position accounts for ﹤0.01% of the portfolio, ranked #3888.

Goldman Sachs first reported a position in ALT in Q2 2013 and has held it in 34 quarters since. The position peaked at $12.6M in Q4 2022. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.

  • Goldman Sachs held 1,350,649 shares of Altimmune worth $4.16M as of Q1 2026.
  • Goldman Sachs bought 1,356 Altimmune shares in Q1 2026, an estimated $5.76K.
  • Altimmune made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #3888 holding.
  • Goldman Sachs first reported a position in Altimmune in Q2 2013 and has held it in 34 quarters since.
  • Goldman Sachs's Altimmune position peaked at $12.6M in Q4 2022.
  • 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.